Sign In
Buy NTLA
$14.75
+1.73 (+13.29%)
At Close: Jun 04, 2026
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 05'th Nov 2024
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
This Beaten-Down Stock Could Soar by 354%, According to Wall Street
08:00am, Monday, 04'th Nov 2024
Maybe the Street is a bit too optimistic on this one.
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
07:30am, Thursday, 31'st Oct 2024
CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
12 High-Growth Stocks That Could Deliver Parabolic Returns
10:00am, Monday, 28'th Oct 2024
These 12 innovative companies could deliver exponential returns over the next quarter century.
Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
12:25pm, Friday, 25'th Oct 2024
Intellia Therapeutics, Inc. achieved positive phase 1/2 results using NTLA-2002 for HAE patients: 8 out of 11 patients taking higher doses of 50 mg of NTLA-2002 were attack-free during the 16-week pri
Why Intellia Therapeutics Stock Plummeted by 20% Today
07:22pm, Thursday, 24'th Oct 2024
Seemingly encouraging results from the lab were met with some notable skepticism.
Intellia Therapeutics, Inc. (NTLA) Call to Discuss NTLA-2002 Phase 2 Study Results Transcript
01:36pm, Thursday, 24'th Oct 2024
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Call to Discuss NTLA-2002 Phase 2 Study Results Call October 24, 2024 11:00 AM ET Company Participants Lina Li - Senior Director, Investor Relations and Corp
2 Biotech Stocks Making Big Moves
01:01pm, Thursday, 24'th Oct 2024
The ever-volatile biotech sector is making noise today.
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?
12:43pm, Thursday, 24'th Oct 2024
On Thursday, Intellia Therapeutics, Inc. NTLA released Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary angioedema (HAE).
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Thursday, 17'th Oct 2024
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street
06:30am, Thursday, 17'th Oct 2024
Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.
Intellia Therapeutics Announces New Date for Upcoming Investor Webcast
07:30am, Thursday, 10'th Oct 2024
- Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET
2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street
06:35am, Wednesday, 09'th Oct 2024
These stocks haven't performed well this year.
NTLA Begins Phase III Study on Hereditary Angioedema Candidate
02:12pm, Tuesday, 08'th Oct 2024
Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE).
